Evaluates anticancer activity of new platinum(IV) complexes, suggesting effective treatment options.
Pt(IV) complexes have garnered extensive attention in relation to their optical properties and biological activity. Herein, we report a new series of luminescent cationic cyclometalated Pt(IV) complexes with phenanthroline‐type ligands [Pt(pbt) 2 (N^N)](ClO 4 ) 2 (pbt = phenylbenzothiazole; N^N = phen 2 , pyraphen 3 , NH 2 ‐phen 4 ), obtained from [Pt(pbt) 2 Cl 2 ] ( 1 ), and their biological activity. Complexes 2 and 3 showed orange emissions, attributed to a 3 IL (pbt) excited state, whereas complex 4 showed dual emission arising from closely lying 3 IL′CT/ 3 L′LCT (L′ = NH 2 ‐phen) states, as confirmed by DFT calculations. Upon blue light irradiation, complexes 1 and 4 generated 1 O 2 and catalyzed NADH photooxidation. Spectroscopic studies indicated BSA binding for complexes 2 and 4 . Among the series, complex 4 exhibited the highest anticancer cytotoxic activity, comparable to cisplatin, and 1 – 3 showed mild phototoxicity. Complex 4 generated intracellular ROS production, microtubule depolymerization and mitochondrial damage in A549 cells, without DNA interaction.
No takes yet. Share an insight, caveat, or question.
Corral-Zorzano et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: